Use of reprogrammed cells to identify therapy for respiratory papillomatosis.
Use of reprogrammed cells to identify therapy for respiratory papillomatosis.
复制标题
DOI：
10.1056/nejmoa1203055
复制
发表时间：
2012-09-27
期刊：
影响因子：
--
通讯作者：
Schlegel R
中科院分区：
文献类型：
--
作者：
Yuan H;Myers S;Wang J;Zhou D;Woo JA;Kallakury B;Ju A;Bazylewicz M;Carter YM;Albanese C;Grant N;Shad A;Dritschilo A;Liu X;Schlegel R
一个有20年复发性呼吸道乳头状瘤病病史的病人，有进行性的双侧肿瘤侵犯肺实质。我们使用条件性重编程从患者的正常和肿瘤肺组织中产生细胞培养物。分析显示，喉肿瘤细胞含有野生型7.9-kb人乳头瘤病毒11型（HPV-11）基因组，而肺肿瘤细胞含有10.4-kb基因组。后者病毒基因组的大小增加是由于启动子和癌基因区域的复制。化学敏感性测试确定伏立诺他为潜在的治疗剂。在治疗开始后3个月，肿瘤大小稳定，在15个月时具有持久的效果。
A patient with a 20-year history of recurrent respiratory papillomatosis had progressive, bilateral tumor invasion of the lung parenchyma. We used conditional reprogramming to generate cell cultures from the patient’s normal and tumorous lung tissue. Analysis revealed that the laryngeal tumor cells contained a wild-type 7.9-kb human papillomavirus virus type 11 (HPV-11) genome, whereas the pulmonary tumor cells contained a 10.4-kb genome. The increased size of the latter viral genome was due to duplication of the promoter and oncogene regions. Chemosensitivity testing identified vorinostat as a potential therapeutic agent. At 3 months after treatment initiation, tumor sizes had stabilized, with durable effects at 15 months.